Read Verzenio for Certain Breast Cancer Conditions

Verzenio, also known by its generic name abemaciclib, is a targeted medicine used for certain types of hormone receptor positive and HER2 negative breast cancer. It may be prescribed for adults with node positive early breast cancer considered at high risk of recurrence, as well as for certain advanced or metastatic cases.

Verzenio is used in combination with endocrine therapy for adults with hormone receptor positive, HER2 negative, node positive early breast cancer that has a high risk of recurrence. Endocrine therapy may include tamoxifen or an aromatase inhibitor. The aim is to help reduce the chance of the cancer returning after primary treatment.

The assessment of recurrence risk can involve factors such as lymph node involvement and characteristics of the tumor. Current prescribing information specifically identifies node positive disease at high risk of recurrence as the eligible early breast cancer setting.

Important points include:

  • Verzenio is a CDK4 and CDK6 inhibitor that helps interfere with signals involved in cancer cell growth.
  • For high risk early breast cancer, it is used alongside endocrine therapy rather than as a replacement for hormone treatment.
  • Treatment suitability depends on the cancer subtype, lymph node status, recurrence risk, previous treatment, and overall health.
  • Doctors may monitor blood counts and other health measures during treatment because some adverse effects can be significant.

Verzenio for Advanced or Metastatic Breast Cancer

For adults with HR positive, HER2 negative advanced or metastatic breast cancer, Verzenio has several approved treatment uses. It may be combined with an aromatase inhibitor as initial endocrine based therapy, combined with fulvestrant when disease progresses following endocrine therapy, or used alone after progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Treatment choice depends on the individual's disease characteristics and previous therapies. Because metastatic breast cancer treatment can change according to response and tolerance, healthcare professionals determine whether Verzenio and a particular combination are appropriate.

Key considerations include:

  • Diarrhea is a common adverse effect and can sometimes become severe, particularly during the first month of treatment.
  • Low white blood cell counts can occur and may increase the risk of serious infections. Blood counts are monitored during treatment.
  • Other potential adverse effects can include fatigue, nausea, decreased appetite, abdominal discomfort, and changes in liver function.
  • Patients should promptly report concerning symptoms to their healthcare team rather than changing or stopping treatment independently.
  • Verzenio is a prescription medicine, so its use and dosing should be determined by a qualified healthcare professional.

Verzenio is an important targeted treatment option for certain HR positive, HER2 negative breast cancers. Its approved uses include specific high risk node positive early breast cancer and several settings of advanced or metastatic disease. The appropriate treatment combination depends on the individual's diagnosis, previous treatment, and overall medical circumstances. This information is provided for educational purposes only and is not a substitute for personalized medical advice. Patients should discuss potential benefits, risks, monitoring requirements, and alternatives with their healthcare professional.